Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Net Margin (2016 - 2020)

Syndax Pharmaceuticals has reported Net Margin over the past 6 years, most recently at 5226.32% for Q4 2020.

  • Quarterly results put Net Margin at 5226.32% for Q4 2020, down 148816.0% from a year ago — trailing twelve months through Sep 2021 was 5226.32% (down 89092.0% YoY), and the annual figure for FY2025 was 165.6%, up 118050.0%.
  • Net Margin for Q4 2020 was 5226.32% at Syndax Pharmaceuticals, roughly flat from 5238.26% in the prior quarter.
  • Over the last five years, Net Margin for SNDX hit a ceiling of 1594.89% in Q4 2017 and a floor of 5238.26% in Q3 2020.
  • Median Net Margin over the past 5 years was 4309.0% (2017), compared with a mean of 4162.45%.
  • Biggest five-year swings in Net Margin: skyrocketed 3175379bps in 2016 and later tumbled -349274bps in 2018.
  • Syndax Pharmaceuticals' Net Margin stood at 3564.92% in 2016, then skyrocketed by 55bps to 1594.89% in 2017, then plummeted by -219bps to 5087.63% in 2018, then increased by 27bps to 3738.16% in 2019, then crashed by -40bps to 5226.32% in 2020.
  • The last three reported values for Net Margin were 5226.32% (Q4 2020), 5238.26% (Q3 2020), and 4382.59% (Q2 2020) per Business Quant data.